cohort 1:Oral 45mg once per day

2 trials

Sponsors

The Second Affiliated Hospital of Zhejiang University School of Medicine

Conditions

Advanced Non-Small Cell Lung Cancer

Phase 1

A phase Ib study for efficacy and safety of Mefatinib (MET-306) in the EGFR-TKI therapy with advanced non-small cell lung cancer

Active, not recruitingChiCTR2000029060

The Second Affiliated Hospital of Zhejiang University School of MedicineAdvanced Non-Small Cell Lung Cancer

Start: 2017-05-04Updated: 2020-01-13

A phase Ib study for efficacy and safety of Mefatinib (MET-306) for the treatment of 1st Line EGFR Mutation in Patients with advanced non-small cell lung cancer

Active, not recruitingChiCTR2000029062

The Second Affiliated Hospital of Zhejiang University School of MedicineAdvanced Non-Small Cell Lung Cancer

Start: 2017-05-11Updated: 2020-01-13